EBC-46 is a new experimental drug for treating cancers in dogs, cats and horses.
In trials with over 100 dogs, cats and horses, intralesional injection of EBC-46 has successfully ablated or significantly palliated a range of advanced, inoperable tumours (melanomas, sarcomas, carcinomas, mast cell tumours and sarcoids) while causing no significant long-term side effects. A topical formulation of EBC-46 has also been used to successfully treat ulcerative squamous cell carcinomas on cats and horses.
EBC-46 is delivered locally in a single treatment by direct injection into tumours, or by topical application onto the tumour surface and works principally by stimulating the patient’s innate immune system to destroy the tumour.
EBC-46 is active against a wide range of tumour types and is potentially useful in treating any solid tumour that can be accessed for direct injection or topical application of the drug.
EBC-46 only works locally at the site of delivery and there is no current evidence to suggest that EBC-46 has any systemic efficacy against metastatic disease in affecting remote secondary tumours.
Clinical trials
QBiotics is currently conducting clinical trials of EBC-46 for treating a range of tumours in dogs, cats and horses through a limited number of veterinary practices.
The clinical trials are focusing on treatment of tumours that are accessible for, and amenable to, direct injection or topical application of the drug including cutaneous and subcutaneous tumours (sarcoids, mast cell tumours, melanomas, squamous and basal cell carcinomas, soft tissue sarcomas), some obstructive tumours of the gastrointestinal and nasopharyngeal tracts, perianal tumours and some oral cancers.
Recruitment for veterinary clinical trials is now closed and no further patient applications can be accepted. EBC-46 will be available through veterinarians following primary registration of the drug which is expected
to be in the second half of 2011. If you would like to receive updates on our progress please join our
E-Newsletter and we will keep you updated.
Please note that we are not in a position to reply to unsolicited emails and phone messages regarding veterinary trials.